Shoulder Innovations reports Q3 results (NYSE:SI)

Shoulder Innovations reported Q3 revenue of $16.2M, up 37.8% year-over-year, exceeding estimates by $0.74M. Adjusted EBITDA loss narrowed to $5.5M from $7.5M in the same period last year. The company expects net revenue growth for the full year.

Original reporting
Published Nov 6, 2026, 8:40 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 8:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SI
Bullish
medium confidence
Mentioned
$SI
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$SIBullishMed
01

Why it matters

The earnings beat on revenue and narrowing loss may prompt short‑term buying interest, but scale is limited.

02

Market read

Micro‑cap earnings release with modest positive surprise; limited broader market effect.

03

What to watch

Cash burn and need for additional financing could offset positive earnings signals.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

Shoulder Innovations (SI) released its Q3 2026 earnings via a press release.

Company-level read

Ticker impact

$SIBullishMedium confidence
Context

Q3 revenue of $16.2M (+37.8% YoY) beats expectations; adjusted EBITDA loss narrows to $5.5M from $7.5M a year ago.

Expected impact

potential modest upside as market prices in improved loss profile

Evidence & confidence

Revenue beat and loss improvement suggest better operating performance, but small scale limits impact.

Market effects

Limited; reflects modest growth in the niche defense‑technology segment.

Minimal; company is US‑based with niche market exposure.

Low; micro‑cap earnings unlikely to affect broader indices.

Counterpoint

Despite revenue beat, the company remains loss‑making; investors may stay cautious.

Key entities

  • Shoulder Innovations, Inc.

    US‑listed defense‑technology firm reporting Q3 results.

Related articles

$SIMedAI 8/10

Shoulder Innovations (SI) Q3 2026 Earnings Call Transcript

Shoulder Innovations reported Q3 2026 net revenue of $16.2M, up 38% YoY, with gross margin at 78.5%. The company raised full-year revenue guidance to $68M-$70M, up 44%-48% YoY. They launched new products, including the InSet Go glenoid implant, and saw strong surgeon adoption and procedural growth. The company expects continued momentum and plans to expand its commercial team.

$SIHigh

Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook 52% Year-to-Date 2026 Revenue Growth Grand Rapids, MI – November 5, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage

$SIMed

22 Humeral Head and Initiates Full Commercial Launch – Ortho Spine News

Shoulder Innovations (NYSE: SI) received FDA 510(k) clearance for its N-22 Humeral Head, a titanium implant for metal-sensitive patients. The company also launched the product commercially. The N-22 Humeral Head complements the N-22 Glenosphere, cleared earlier this year, for use in shoulder arthroplasty procedures. According to the company, this expansion may enhance surgeon relationships and operational centers. Shoulder Innovations focuses on shoulder surgical care, offering advanced implant

$SIMed

Shoulder Innovations Q2 Earnings Call Highlights

Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.